Ustekinumab biosimilar for IBD/Psoriasis

Drug Overview

OTULFI (ustekinumab-aauz) is a high-affinity, fully human MONOCLONAL ANTIBODY and a newly approved Ustekinumab biosimilar for IBD/Psoriasis within the IMMUNOLOGY drug category. It is classified as an INTERLEUKIN-12 (IL-12) AND INTERLEUKIN-23 (IL-23) INHIBITOR. As a TARGETED THERAPY, Otulfi offers a clinically equivalent, more accessible alternative to its reference product (Stelara) for patients managing chronic, immune-mediated inflammatory conditions of the skin and gastrointestinal tract.

• Generic Name: Ustekinumab-aauz
• US Brand Name: Otulfi
• Drug Class: IL-12/IL-23 Inhibitor; BIOLOGIC; IMMUNOMODULATOR
• Route of Administration: Intravenous (IV) Infusion (Induction) and Subcutaneous (SC) Injection (Maintenance)
• FDA Approval Status: FDA-approved as a BIOSIMILAR for the treatment of Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis.

As a BIOSIMILAR, Otulfi has undergone rigorous analytical and clinical testing (2020–2025) to confirm it has no clinically meaningful differences in safety, purity, or potency compared to the original biologic. It functions as a potent IMMUNOMODULATOR for patients who require advanced systemic therapy.

What Is It and How Does It Work? (Mechanism of Action)

Molecular and Cellular Level Action

The drug interrupts the inflammatory cascade through the following interactions:

1. p40 Subunit Binding: Otulfi binds with high specificity to the p40 subunit of the IL-12 and IL-23 cytokines.
2. Receptor Blockade: By binding to these cytokines, the drug prevents them from attaching to the IL-12Rβ1 receptor protein found on the surface of immune cells.
3. Th1 and Th17 Pathway Interference: This blockade prevents the signaling that leads to the activation and differentiation of T-helper (Th1 and Th17) cells.
4. Cytokine Suppression: By silencing these pathways, Otulfi reduces the production of downstream inflammatory markers (such as TNF-alpha and IL-17), effectively calming the “immune storm” in the skin and intestinal mucosa.
5. Selective Impact: Unlike broad immunosuppressants, this TARGETED THERAPY specifically addresses the pathways responsible for autoimmune tissue damage while leaving other parts of the immune system intact.

FDA-Approved Clinical Indications

Primary Indication: IBD and Psoriasis

Otulfi is indicated for the treatment of several chronic inflammatory conditions:

• Crohn’s Disease (CD): For adult patients with moderately to severely active disease.
• Ulcerative Colitis (UC): For adult patients with moderately to severely active disease.
• Plaque Psoriasis: For adult and pediatric patients (6 years and older) with moderate-to-severe disease who are candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis (PsA): For adult patients with active PsA to improve joint symptoms and physical function.

Primary Immunology Indications

• Mucosal Healing: Promoting the resolution of intestinal ulcers to prevent systemic damage and strictures in IBD.
• Skin Clearance: Reducing the over-proliferation of skin cells (keratinocytes) and redness in psoriasis.
• Joint Protection: Slowing the progression of structural damage in patients with psoriatic arthritis.

Dosage and Administration Protocols

Otulfi administration depends on the condition. For IBD, it involves a “Dual-Route” protocol, whereas for Psoriasis and PsA, it is exclusively subcutaneous.

Dose Adjustments and Special Populations

• Weight-Based Dosing (Psoriasis): Patients weighing >100 kg typically require the 90 mg dose rather than the 45 mg dose.
• Pediatric Transition: Pediatric patients with psoriasis are dosed based on body weight to ensure safety in the developing immune system.
• IBD Maintenance: The first SC maintenance dose is given 8 weeks after the initial IV induction.

Clinical Efficacy and Research Results

The approval of Otulfi is supported by comprehensive “Biosimilarity” data, including the FRESCO clinical trials (2023–2025).

Numerical Research Data

• Psoriasis Clearance: In Phase 3 trials, approximately 65% to 75% of patients achieved a PASI 75 (75% improvement in skin) by week 12.
• IBD Remission: Clinical data showed that induction with ustekinumab-aauz achieved clinical response in roughly 50% of patients with Crohn’s Disease within 8 weeks.
• Safety Equivalence: Research through 2026 confirms that the safety profile, including the rate of infection, is identical to the reference biologic.

Recent Research (2024–2026)

Current research in PRECISION IMMUNOLOGY is investigating “Therapeutic Drug Monitoring” (TDM) for Otulfi. 2025 studies have explored the “Target Trough Concentration” in IBD patients, suggesting that maintaining a specific blood level of the drug is key to long-term mucosal healing. Additionally, research into “Switch Studies” has confirmed that patients can safely transition from the reference biologic to Otulfi without any “loss of response” or increased risk of Anti-Drug Antibodies (ADAs).

Safety Profile and Side Effects

While Otulfi is a TARGETED THERAPY, it modulates the immune response and requires careful screening.

Common Side Effects (>10%)

• Upper Respiratory Infections: Nasopharyngitis and sinusitis.
• Headache: Usually mild and transient.
• Fatigue: Reported more frequently during the induction phase.
• Injection Site Reactions: Redness or swelling where the SC shot was administered.

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, fungal, or viral infections (including Tuberculosis).
• Malignancies: A theoretical increased risk of non-melanoma skin cancers.
• Posterior Reversible Encephalopathy Syndrome (PRES): An extremely rare but serious brain condition.
• Non-Infectious Pneumonia: Rare reports of interstitial lung inflammation.

Management Strategies

• Screening: Mandatory QuantiFERON-TB Gold test and Hepatitis B/C screening before the first dose.
• Vigilance: Monitor for signs of PRES (confusion, seizures, or vision changes).
• Skin Surveillance: Annual skin exams for all patients on long-term IMMUNOMODULATOR therapy.

Research Areas

Direct Clinical Connections

Active research is exploring the role of IL-23 in the “Gut-Skin Axis.” Scientists are investigating how Otulfi provides a unified benefit for patients who suffer from both Crohn’s and Psoriasis by targeting the shared p40 signaling pathway.

Generalization and Advancements

• Novel Delivery Systems: Research into high-concentration autoinjectors to improve the ease of home administration.
• Precision Immunology: Using “Molecular Profiling” of tissue biopsies to predict whether a patient will respond better to IL-12/23 inhibition compared to other pathways like TNF or JAK.
• Biosimilar Accessibility: The 2026 market expansion of Otulfi is expected to significantly lower healthcare costs for patients with chronic autoimmune diseases.

Disclaimer: The research mentioned regarding molecular profiling of biopsies to predict therapeutic response, the investigation into the “Gut-Skin Axis” as a unified treatment target for IL-23 inhibition, and the development of high-concentration autoinjectors is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: CBC, LFTs, and baseline CRP/ESR.
• Infection Screening: Tuberculosis (TB) and Hepatitis tests are mandatory.
• Vaccination History: Live vaccines (e.g., MMR, Yellow Fever) are contraindicated during treatment and for 15 weeks after the last dose.

Monitoring and Precautions

• Vigilance: Report any persistent cough, fevers, or unintended weight loss.
• Loss of Response: If symptoms return, clinicians may check for ADAs or adjust the dosing frequency.
• Lifestyle:
  • Sun Protection: Daily SPF 50+ is recommended due to the potential risk of skin cancer.
  • Joint Care: Maintain low-impact exercise (swimming/cycling) for patients with PsA.

Do’s and Don’ts

• DO store Otulfi in the refrigerator (2°C to 8°C) and protect it from light.
• DO allow the pre-filled syringe to reach room temperature for 30 minutes before injecting.
• DON’T use the medication if the liquid is cloudy, discolored, or contains large particles.
• DON’T receive live vaccines while on this BIOLOGIC without consulting your immunologist.

Legal Disclaimer

This guide is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of OTULFI (ustekinumab-aauz) must be managed by a specialist in dermatology, gastroenterology, or rheumatology. Never disregard professional medical advice based on information provided in this guide.